Trade Predictive Oncology Inc. - POAI CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.10 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 2.76 |
Open* | 2.74 |
1-Year Change* | 568.29% |
Day's Range* | 2.53 - 2.74 |
52 wk Range | 2.47-13.88 |
Average Volume (10 days) | 14.70K |
Average Volume (3 months) | 358.54K |
Market Cap | 11.05M |
P/E Ratio | -100.00K |
Shares Outstanding | 4.06M |
Revenue | 1.81M |
EPS | -4.64 |
Dividend (Yield %) | N/A |
Beta | 1.29 |
Next Earnings Date | Mar 19, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 28, 2024 | 2.53 | -0.21 | -7.66% | 2.74 | 2.74 | 2.53 |
Mar 27, 2024 | 2.76 | 0.09 | 3.37% | 2.67 | 2.76 | 2.57 |
Mar 26, 2024 | 2.64 | 0.01 | 0.38% | 2.63 | 2.65 | 2.52 |
Mar 25, 2024 | 2.59 | 0.06 | 2.37% | 2.53 | 2.72 | 2.52 |
Mar 22, 2024 | 2.52 | -0.01 | -0.40% | 2.53 | 2.61 | 2.43 |
Mar 21, 2024 | 2.56 | 0.01 | 0.39% | 2.55 | 2.66 | 2.53 |
Mar 20, 2024 | 2.55 | -0.01 | -0.39% | 2.56 | 2.56 | 2.53 |
Mar 19, 2024 | 2.57 | 0.00 | 0.00% | 2.57 | 2.61 | 2.57 |
Mar 18, 2024 | 2.68 | 0.07 | 2.68% | 2.61 | 2.75 | 2.55 |
Mar 15, 2024 | 2.54 | -0.05 | -1.93% | 2.59 | 2.65 | 2.44 |
Mar 14, 2024 | 2.60 | -0.34 | -11.56% | 2.94 | 2.94 | 2.59 |
Mar 13, 2024 | 2.83 | -0.01 | -0.35% | 2.84 | 3.05 | 2.78 |
Mar 12, 2024 | 2.83 | -0.05 | -1.74% | 2.88 | 2.94 | 2.81 |
Mar 11, 2024 | 2.88 | -0.05 | -1.71% | 2.93 | 2.94 | 2.80 |
Mar 8, 2024 | 2.88 | 0.04 | 1.41% | 2.84 | 2.98 | 2.84 |
Mar 7, 2024 | 2.83 | 0.03 | 1.07% | 2.80 | 2.85 | 2.77 |
Mar 6, 2024 | 2.79 | -0.09 | -3.12% | 2.88 | 2.95 | 2.74 |
Mar 5, 2024 | 2.85 | -0.05 | -1.72% | 2.90 | 2.93 | 2.78 |
Mar 4, 2024 | 2.94 | -0.04 | -1.34% | 2.98 | 3.00 | 2.88 |
Mar 1, 2024 | 2.98 | -0.09 | -2.93% | 3.07 | 3.13 | 2.97 |
Predictive Oncology Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Monday, April 1, 2024 | ||
Time (UTC) 12:30 | Country US
| Event Q4 2023 Predictive Oncology Inc Earnings Call Q4 2023 Predictive Oncology Inc Earnings CallForecast -Previous - |
Thursday, April 18, 2024 | ||
Time (UTC) 20:00 | Country US
| Event Predictive Oncology Inc Annual Shareholders Meeting Predictive Oncology Inc Annual Shareholders MeetingForecast -Previous - |
Monday, May 13, 2024 | ||
Time (UTC) 10:59 | Country US
| Event Q1 2024 Predictive Oncology Inc Earnings Release Q1 2024 Predictive Oncology Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 1.50546 | 1.42068 | 1.25227 | 1.41157 | 1.41166 |
Revenue | 1.50546 | 1.42068 | 1.25227 | 1.41157 | 1.41166 |
Cost of Revenue, Total | 0.50511 | 0.48702 | 0.44719 | 0.53181 | 0.41576 |
Gross Profit | 1.00035 | 0.93366 | 0.80508 | 0.87976 | 0.9959 |
Total Operating Expense | 27.5391 | 21.8493 | 28.609 | 24.6374 | 9.27303 |
Selling/General/Admin. Expenses, Total | 12.4696 | 11.7067 | 10.9369 | 11.6941 | 6.99615 |
Interest Expense (Income) - Net Operating | |||||
Other Operating Expenses, Total | 3.79843 | 2.69857 | 2.35171 | 2.96013 | 1.86112 |
Operating Income | -26.0336 | -20.4286 | -27.3567 | -23.2258 | -7.86137 |
Net Income Before Taxes | -25.7376 | -20.3188 | -25.8844 | -19.3908 | -10.0865 |
Net Income After Taxes | -25.7376 | -19.6572 | -25.8844 | -19.3908 | -10.0865 |
Net Income Before Extra. Items | -25.7376 | -19.6572 | -25.8844 | -19.3908 | -10.0865 |
Net Income | -25.7376 | -19.6572 | -25.8844 | -19.3908 | -10.0865 |
Income Available to Common Excl. Extra. Items | -25.7376 | -19.6572 | -26.4387 | -19.6807 | -10.0865 |
Income Available to Common Incl. Extra. Items | -25.7376 | -19.6572 | -26.4387 | -19.6807 | -10.0865 |
Diluted Net Income | -25.7376 | -19.6572 | -26.4387 | -19.6807 | -10.0865 |
Diluted Weighted Average Shares | 3.6499 | 2.7438 | 0.59751 | 0.14351 | 0.06408 |
Diluted EPS Excluding Extraordinary Items | -7.0516 | -7.16421 | -44.2483 | -137.141 | -157.401 |
Diluted Normalized EPS | -4.10195 | -5.5161 | -19.3562 | -71.2816 | -157.401 |
Interest Income (Expense), Net Non-Operating | 0.11565 | 0.1649 | 3.05591 | 5.72462 | -2.29358 |
Other, Net | 0.18037 | -0.0551 | -1.58359 | -1.88957 | 0.06848 |
Total Adjustments to Net Income | 0 | -0.55429 | -0.28994 | ||
Unusual Expense (Income) | 10.7659 | 6.95707 | 14.8732 | 9.45132 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 0.49011 | 0.2399 | 0.36347 | 0.45583 | 0.37159 |
Revenue | 0.49011 | 0.2399 | 0.36347 | 0.45583 | 0.37159 |
Cost of Revenue, Total | 0.15976 | 0.12014 | 0.15344 | 0.10815 | 0.13408 |
Gross Profit | 0.33035 | 0.11976 | 0.21003 | 0.34768 | 0.23751 |
Total Operating Expense | 4.44934 | 3.70488 | 8.3269 | 4.58658 | 10.897 |
Selling/General/Admin. Expenses, Total | 3.1266 | 2.69956 | 3.49751 | 3.6213 | 2.62272 |
Other Operating Expenses, Total | 0.99304 | 0.87852 | 1.14111 | 0.85713 | 0.90911 |
Operating Income | -3.95923 | -3.46498 | -7.96343 | -4.13075 | -10.5254 |
Interest Income (Expense), Net Non-Operating | 0.00731 | 0.00095 | 0.00827 | 0.01022 | 0.09525 |
Other, Net | 0.02855 | 0.04223 | 0.03905 | 0.06105 | 0.03883 |
Net Income Before Taxes | -3.92337 | -3.4218 | -7.91611 | -4.05948 | -10.3913 |
Net Income After Taxes | -3.92337 | -3.4218 | -7.91611 | -4.05948 | -10.3913 |
Net Income Before Extra. Items | -3.92337 | -3.4218 | -7.91611 | -4.05948 | -10.3913 |
Net Income | -3.92337 | -3.4218 | -7.91611 | -4.05948 | -10.3913 |
Income Available to Common Excl. Extra. Items | -3.92337 | -3.4218 | -7.91611 | -4.05948 | -10.3913 |
Income Available to Common Incl. Extra. Items | -3.92337 | -3.4218 | -7.91611 | -4.05948 | -10.3913 |
Diluted Net Income | -3.92337 | -3.4218 | -7.91611 | -4.05948 | -10.3913 |
Diluted Weighted Average Shares | 3.99651 | 3.9681 | 3.93693 | 3.91919 | 3.44483 |
Diluted EPS Excluding Extraordinary Items | -0.9817 | -0.86233 | -2.01073 | -1.0358 | -3.0165 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.94094 | -0.86233 | -1.11286 | -1.0358 | -0.91738 |
Unusual Expense (Income) | 0.16291 | 3.53484 | 0 | 7.23109 | |
Total Adjustments to Net Income | |||||
Depreciation / Amortization | 0.00704 | 0.00667 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 23.36 | 29.4583 | 1.51424 | 0.79826 | 1.45153 |
Cash and Short Term Investments | 22.0715 | 28.2026 | 0.67833 | 0.15083 | 0.16215 |
Cash | 22.0715 | 28.2026 | 0.67833 | 0.15083 | 0.16215 |
Short Term Investments | 0 | ||||
Total Receivables, Net | 0.3312 | 0.3542 | 0.25688 | 0.29706 | 0.72988 |
Accounts Receivable - Trade, Net | 0.3312 | 0.3542 | 0.25688 | 0.29706 | 0.2326 |
Total Inventory | 0.43049 | 0.38768 | 0.28954 | 0.19016 | 0.24107 |
Prepaid Expenses | 0.5268 | 0.51378 | 0.28949 | 0.16022 | 0.31843 |
Total Assets | 25.7346 | 43.7713 | 13.0604 | 22.3755 | 3.709 |
Property/Plant/Equipment, Total - Net | 2.04515 | 3.32603 | 5.21805 | 2.23754 | 0.18045 |
Intangibles, Net | 0.25387 | 3.96212 | 3.3981 | 3.64941 | 0.9645 |
Total Current Liabilities | 3.88267 | 3.24051 | 9.33692 | 10.8739 | 3.65553 |
Accounts Payable | 0.94345 | 1.02177 | 1.37207 | 3.15564 | 0.44569 |
Accrued Expenses | 2.32331 | 1.9023 | 3.18552 | 2.83111 | 1.27911 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 4.7958 | 1.63491 |
Other Current Liabilities, Total | 0.61591 | 0.31643 | 0.34741 | 0.09137 | 0.29581 |
Total Liabilities | 3.96875 | 3.50559 | 10.4178 | 11.1442 | 3.65553 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 0.08608 | 0.26508 | 1.08083 | 0.27026 | |
Total Equity | 21.7659 | 40.2657 | 2.64268 | 11.2313 | 0.05347 |
Preferred Stock - Non Redeemable, Net | 0.00079 | 0.00079 | 0.00079 | 0.0358 | 0.00079 |
Common Stock | 0.78763 | 0.65615 | 0.19805 | 0.04057 | 0.14092 |
Additional Paid-In Capital | 174.755 | 167.649 | 110.827 | 93.6537 | 63.0197 |
Retained Earnings (Accumulated Deficit) | -153.778 | -128.04 | -108.383 | -82.4987 | -63.1079 |
Other Equity, Total | |||||
Total Liabilities & Shareholders’ Equity | 25.7346 | 43.7713 | 13.0604 | 22.3755 | 3.709 |
Total Common Shares Outstanding | 3.93814 | 3.28073 | 0.99024 | 0.20283 | 0.07046 |
Total Preferred Shares Outstanding | 0.07925 | 0.07925 | 0.07925 | 3.5795 | 0.07925 |
Note Receivable - Long Term | 0 | 1.11252 | |||
Property/Plant/Equipment, Total - Gross | 4.92275 | 5.39436 | 6.5499 | 3.00912 | |
Accumulated Depreciation, Total | -2.8776 | -2.06834 | -1.33185 | -0.77157 | |
Goodwill, Net | 0 | 6.85779 | 2.81379 | 15.6903 | |
Other Long Term Assets, Total | 0.07562 | 0.16707 | 0.11626 | ||
Current Port. of LT Debt/Capital Leases | 0 | 4.43193 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 13.5205 | 15.9695 | 19.7802 | 23.36 | 26.8573 |
Cash and Short Term Investments | 11.915 | 14.7638 | 18.5971 | 22.0715 | 25.3937 |
Cash | 11.915 | 14.7638 | 18.5971 | 22.0715 | 25.3937 |
Total Receivables, Net | 0.54476 | 0.43085 | 0.28276 | 0.3312 | 0.32471 |
Accounts Receivable - Trade, Net | 0.54476 | 0.43085 | 0.28276 | 0.3312 | 0.32471 |
Total Inventory | 0.43999 | 0.3937 | 0.38029 | 0.43049 | 0.49372 |
Prepaid Expenses | 0.62069 | 0.38123 | 0.52001 | 0.5268 | 0.64515 |
Total Assets | 18.1669 | 20.967 | 25.0616 | 25.7346 | 33.1662 |
Property/Plant/Equipment, Total - Net | 4.26297 | 4.5572 | 4.83434 | 2.04515 | 2.53167 |
Property/Plant/Equipment, Total - Gross | 7.69956 | 7.83767 | 7.9417 | 4.92275 | 5.24453 |
Accumulated Depreciation, Total | -3.43659 | -3.28047 | -3.10737 | -2.8776 | -2.71287 |
Goodwill, Net | 0 | 0 | |||
Intangibles, Net | 0.25932 | 0.26618 | 0.27297 | 0.25387 | 3.7016 |
Other Long Term Assets, Total | 0.1241 | 0.1741 | 0.1741 | 0.07562 | 0.07562 |
Total Current Liabilities | 4.17189 | 3.76334 | 3.91035 | 3.88267 | 3.46808 |
Accounts Payable | 1.16823 | 1.01348 | 1.42448 | 0.94345 | 0.91727 |
Accrued Expenses | 2.36638 | 2.11639 | 1.83375 | 2.32331 | 2.03334 |
Notes Payable/Short Term Debt | 0.26022 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.37707 | 0.63347 | 0.65212 | 0.61591 | 0.51746 |
Total Liabilities | 6.51551 | 6.26195 | 6.50719 | 3.96875 | 3.57333 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 2.34362 | 2.49861 | 2.59685 | 0.08608 | 0.10525 |
Total Equity | 11.6514 | 14.7051 | 18.5544 | 21.7659 | 29.5929 |
Preferred Stock - Non Redeemable, Net | 0.00079 | 0.00079 | 0.00159 | 0.00079 | 0.00079 |
Common Stock | 0.04033 | 0.04006 | 0.0397 | 0.78763 | 0.78407 |
Additional Paid-In Capital | 175.897 | 175.787 | 175.713 | 174.755 | 174.67 |
Retained Earnings (Accumulated Deficit) | -164.287 | -161.123 | -157.2 | -153.778 | -145.862 |
Total Liabilities & Shareholders’ Equity | 18.1669 | 20.967 | 25.0616 | 25.7346 | 33.1662 |
Total Common Shares Outstanding | 4.03329 | 4.0063 | 3.96999 | 3.93814 | 3.92037 |
Total Preferred Shares Outstanding | 0.07925 | 0.07925 | 0.07925 | 0.07925 | 0.07925 |
Current Port. of LT Debt/Capital Leases |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -25.7376 | -19.6572 | -25.8844 | -19.3908 | -10.0865 |
Cash From Operating Activities | -12.3708 | -12.2089 | -12.2577 | -8.73245 | -5.28796 |
Cash From Operating Activities | 1.31308 | 1.3403 | 1.02485 | 0.70488 | 0.14763 |
Non-Cash Items | 11.1871 | 7.30233 | 13.8147 | 8.07998 | 3.76659 |
Cash Interest Paid | 0.00382 | 0.69051 | 0.14583 | ||
Changes in Working Capital | 0.86669 | -1.19438 | -1.21288 | 1.87345 | 0.8843 |
Cash From Investing Activities | -0.4757 | -10.6075 | -0.16746 | -0.59909 | -1.11065 |
Capital Expenditures | -0.4757 | -0.96232 | -0.36078 | -0.02661 | -0.232 |
Other Investing Cash Flow Items, Total | 0 | -9.64521 | 0.19332 | -0.57248 | -0.87865 |
Cash From Financing Activities | 6.71541 | 50.3408 | 12.9527 | 9.32022 | 5.79457 |
Issuance (Retirement) of Stock, Net | 6.71541 | 55.7015 | 11.8851 | 7.98702 | 3.60957 |
Issuance (Retirement) of Debt, Net | 0 | 1.28948 | 1.53549 | 2.185 | |
Net Change in Cash | -6.13109 | 27.5243 | 0.5275 | -0.01132 | -0.60404 |
Financing Cash Flow Items | 0 | -5.36071 | -0.22191 | -0.20229 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -3.4218 | -25.7376 | -17.8215 | -13.762 | -3.37072 |
Cash From Operating Activities | -3.42776 | -12.3708 | -9.13581 | -6.42781 | -3.0937 |
Cash From Operating Activities | 0.23785 | 1.31308 | 0.98038 | 0.64944 | 0.3236 |
Non-Cash Items | 0.02035 | 11.1871 | 7.5351 | 7.42432 | 0.19793 |
Changes in Working Capital | -0.26416 | 0.86669 | 0.17023 | -0.73953 | -0.24452 |
Cash From Investing Activities | -0.04664 | -0.4757 | -0.4121 | -0.26842 | -0.08024 |
Capital Expenditures | -0.04664 | -0.4757 | -0.4121 | -0.26842 | -0.08024 |
Cash From Financing Activities | 0 | 6.71541 | 6.73903 | 6.74306 | 0.08689 |
Financing Cash Flow Items | 0 | 0 | 0 | 0 | |
Issuance (Retirement) of Stock, Net | 0 | 6.71541 | 6.73903 | 6.74306 | 0.08689 |
Net Change in Cash | -3.4744 | -6.13109 | -2.80888 | 0.04684 | -3.08705 |
Cash Interest Paid | 0.00382 | 0.00375 | 0.00144 | ||
Issuance (Retirement) of Debt, Net | |||||
Other Investing Cash Flow Items, Total | 0 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Predictive Oncology Inc. Company profile
Predictive Oncology Inc. provides various healthcare products and services primarily in the United States. The company operates in three segments: Helomics, Soluble, and Skyline. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers STREAMWAY System, a wall-mounted fully automated system that disposes suction fluid providing uninterrupted performance for physicians while virtually eliminating healthcare workers'' exposure to infectious fluids collected during surgical and other patient procedures, as well as proprietary cleaning fluid and filters to users of its systems. The company also provides contract research organization (CRO) and AI-driven predictive models of tumor drug response to improve clinical outcomes to assist pharmaceutical, diagnostic, and biotech industries; and soluble and stable formulations for proteins, including vaccines, antibodies, and other protein therapeutics, as well as develops tumor models for precision cancer therapy and drug development. Its CRO services enhance the effectiveness of cancer therapy using the power of artificial intelligence (AI) applied to diseases databases. The company sells its medical device products directly to hospitals and other medical facilities through employed sales representatives, independent contractors, and distributors. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.Industry: | Medical Equipment, Supplies & Distribution (NEC) |
2915 Commers Dr Ste 900
EAGAN
MINNESOTA 55121-2363
US
Income Statement
- Annual
- Quarterly
News
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com